Phase 2 N=27 Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
X-linked Retinoschisis
Primary: Number of Participants Experiencing Adverse Events — 6; 7; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
Retinoschisis · X-Linked
Primary: Adverse Events (AEs) Affecting Ocular Function That Differ Clinically From Those Expected in the Normal Course of Progression of XLRS — 3; 3; 12; 6 events
N/A N=26 Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 2 N=78 DHA and X-Linked Retinitis Pigmentosa
Retinitis Pigmentosa · X-linked Genetic Diseases
Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30
Phase 2 N=8 A Study in Subjects With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
Phase 1 N=14 A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Rhegmatogenous Retinal Detachment - Macula Off
Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
Phase 2 N=24 Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
Age Related Macular Degeneration
Primary: Best-corrected Visual Acuity — 52.9 ETDRS letters
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
Phase 4 N=46 Study for Recalcitrant Age Related Macular Degeneration
Age Related Macular Degeneration
Primary: The Number of Patients With no Fluid on OCT — 10 participants
Phase 2 N=109 Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
Diabetic Retinopathy
Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants
N/A N=218 Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
Uveitis · Iritis · Iridocyclitis
Primary: Macular Thickness Measured With the OCT; in Relation to Age, Sex, Reproductive Factors and the Use of Anti-inflammatory Eye Drops in Health; in Uncomplicated Anterior…
Phase 2 N=45 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
X-Linked Retinitis Pigmentosa
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…
N/A N=5 Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department
Retinal Detachment
Primary: Number of Participants With Retinal Detachment Per Ultrasound Assessment — 5 Participants
Phase 2 N=18 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
X-Linked Retinitis Pigmentosa
Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=8 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Proliferative Diabetic Retinopathy
Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…
N/A N=40 Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Retinitis Pigmentosa · AMD
Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05
Phase 2 N=22 Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
Diabetic Macular Edema
Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…
Phase 2 N=31 TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Retinal Vein Occlusion · Macula Edema
Primary: Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye — 1; 1; 1 Participants
Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
N/A N=20 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
Retinal Detachment · Vitreoretinopathy Proliferative
Primary: The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) — 6 Participants
Phase 3 N=377 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
Diabetes Mellitus · Macular Edema
Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
N/A N=323 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Retinal Vein Occlusion · Macular Edema
Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…
Phase 2 N=83 Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Best Corrected Visual Acuity (BCVA) — 3.9; 1.3; 2.6 Letters correct — p=0.582
Phase 2 N=7 Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment…